



## The Use of Epigenetic Biomarkers as Diagnostic and Therapeutic Options 2.0

Guest Editor:

**Dr. Yuen Yee Cheng**

Institute for Biomedical Materials  
and Devices, University of  
Technology Sydney, 15  
Broadway, Ultimo, NSW 2007,  
Australia

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editor

The present Special Issue aims to publish high-quality research articles as well as review contributions on a variety of topics related to epigenetic biomarkers, COVID-19, and therapeutic options.

Potential topics include, but are not limited to:

- Types of epigenetic biomarkers used in clinical practice for different diseases:
  - DNA methylation of circulating or non-circulating DNA;
  - Histone modification (e.g., histone methylation and acetylation);
  - microRNA, circular RNA, and other non-coding RNA;
- Methods of new epigenetic biomarker discovery;
- The potential of liquid biopsy for epigenetic biomarker detection;
- The process of developing of epigenetic biomarkers as treatment options for clinical practice.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ernesto Guccione

Icahn School of Medicine at  
Mount Sinai, Hess Center for  
Science and Medicine, New York,  
NY 10029, USA

## Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

*Epigenomes* (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [ESCI \(Web of Science\)](#), [PMC](#), [PubMed](#), [Embase](#), [PubAg](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

## Contact Us

*Epigenomes* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/epigenomes](http://mdpi.com/journal/epigenomes)  
[epigenomes@mdpi.com](mailto:epigenomes@mdpi.com)  
[X@Epigenomes](#)